Previous studies have shown that CRC patients who received neoadjuvant therapy may have an almost complete loss of MSH6 or only nucleolus staining, resulting in dMMR, but that the MSI status is MSS (Bao et al., 2010; Goldstein et al., 2017). Here, MSH6 is linked to colorectal carcinoma.